Emerging biopharma (EBP) companies are reshaping drug development, driving a significant share of global innovation and clinical activity. In 2025, EBPs originated 61% of new drugs and launched 81% of those they discovered, while contributing 68% of global clinical trial starts. These companies now lead major areas such as oncology, rare diseases, and cell and gene therapies, supported by diverse business models ranging from virtual biotechs to integrated organizations. However, they face challenges including limited funding, complex regulations, talent shortages, and competition in crowded markets. To sustain growth, EBPs are adopting flexible trial designs, innovative enrollment approaches, strategic partnerships, and practical applications of AI to improve efficiency and accelerate deve

Join for free to read